Stay updated with breaking news from Deep Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deep Bio today announced the publication of a study evaluating the performance of its AI algorithm for breast cancer analysis to accurately differentiate between invasive ductal carcinoma (IDC) lesions from non-invasive ductal carcinoma in situ (DCIS) lesions in biopsies taken after breast cancer surgery.
/PRNewswire/ -- DeepBio announced today that it has been awarded the CES Innovation Award as the first Korean cancer diagnosis A.I. company in CES 2024, the...
/PRNewswire/ -- Deep Bio, a leading AI healthcare company specializing in deep learning and cancer pathology, is proud to announce its participation in the...
"In April 2023, Indica Labs Inc. (US) signed an agreement with Lunit Inc. (South Korea). The agreement helped to provide a fully interoperable solution between Indica Labs' HALO AP image management software platform and